WINT (Windtree Therapeutics Inc.) Earnings per share for the last four quarters

Liquidity shortages and the risk of share dilution are putting pressure on Windtree Therapeutics (WINT). Reviewing the chart on GURU.Markets, we see that the current EPS YoY TTM growth rate of 73.30 reflects recent values. A diversified small-molecule portfolio reduces FDA regulatory barriers, yet the fierce competition for cardiology drug efficacy in this niche remains a serious challenge for the business.

Windtree - WINT Net earnings per share (EPS TTM) (period 02/11/2024 - 02/20/2024)

Financial and market metric breakdowns for Windtree (WINT)

- share price and consensus valuation forecast:

Share Price Windtree Therapeutics|WINT - Consensus Target

- business market valuation indicators:

Market Value Windtree Therapeutics Inc.|WINT - Total Company Value

- business book valuation details:

Accounting Value of a Share Windtree Therapeutics|WINT - Book Capitalization|Market-to-Book Ratio windtreetx.com|WINT - Company Total Assets

- debt and liquidity data:

Debt to Capital Windtree Therapeutics|WINT - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Windtree Therapeutics|WINT - Company Total Debt|Debt to Book Capital Windtree Therapeutics Inc.|WINT - Company Long-Term Debts|Company Short-Term Loans and Borrowings Windtree Therapeutics|Immediate Liquidity windtreetx.com

- financial results and valuation multiples details:

WINT - Company Net Income|Expected Net Income Windtree Therapeutics|WINT - P/E Multiple|Forward P/E Multiple Windtree Therapeutics|WINT - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Windtree Therapeutics Inc.|WINT - Operating profit EBITDA|Net earnings per one share for the last twelve months Windtree Therapeutics|WINT - Net earnings per share for the last 12 months|Quarterly EPS earnings growth windtreetx.com|WINT - Net earnings per share growth this year|Projected earnings per share increase next year Windtree Therapeutics

- sales and revenue indicators:

WINT - Revenue and Sales Volume|Company Future Sales Windtree Therapeutics|WINT - P/S Multiple|Forward Price-to-Revenue Multiple Windtree Therapeutics Inc.

Fundamental valuation:Windtree Therapeutics, Inc. (WINT)

Windtree Therapeutics focuses on developing bioengineered products for heart tissue regeneration. The EPS YoY TTM percentage trend reflects the annual growth rate of net income per share, recalculated based on the latest 10-Q reports. This indicator allows for tracking the actual business trajectory by excluding random fluctuations. Sharp peaks on the chart often reflect inflated market expectations, increasing the risk of a correction. Stable growth of this metric confirms the effectiveness of the company's R&D strategy.

Competitor analysis for Windtree Therapeutics